Discussion
Enrollment is now complete in a Phase 3 trial assessing the safety and efficacy of solengepras (CVN424), Cerevance’s experimental non-dopaminergic therapy, in people with Parkinson’s disease. The Phase 3 ARISE trial (NCT06553027) is assessing solengepras’ efficacy, when given with levodopa and other standard Parkinson’s medications, in 341 patients with…
